IL-6 production by BMMC from patients with MGUS and MM
| Disease status . | BMMC (%) . | |
|---|---|---|
| Syndecan-1−/IL-6+ . | Syndecan-1+/IL-6+ . | |
| Active MM (n = 31) | 40.5 ± 12.9 | 42.4 ± 18.6* |
| Primary refractory/resistant relapse (n = 11) | 33.1 ± 10.6 | 52.8 ± 13.5* |
| Recent diagnosis (n = 7) | 44.8 ± 12.2 | 31.3 ± 16.6* |
| Relapse (n = 13) | 44.3 ± 13.3 | 39.5 ± 13.4* |
| Remission MM (n = 16) | 43.2 ± 12.3 | 3.7 ± 1.8 |
| MGUS (n = 15) | 39.8 ± 9.3 | 6.8 ± 4.1 |
| Disease status . | BMMC (%) . | |
|---|---|---|
| Syndecan-1−/IL-6+ . | Syndecan-1+/IL-6+ . | |
| Active MM (n = 31) | 40.5 ± 12.9 | 42.4 ± 18.6* |
| Primary refractory/resistant relapse (n = 11) | 33.1 ± 10.6 | 52.8 ± 13.5* |
| Recent diagnosis (n = 7) | 44.8 ± 12.2 | 31.3 ± 16.6* |
| Relapse (n = 13) | 44.3 ± 13.3 | 39.5 ± 13.4* |
| Remission MM (n = 16) | 43.2 ± 12.3 | 3.7 ± 1.8 |
| MGUS (n = 15) | 39.8 ± 9.3 | 6.8 ± 4.1 |
IL-6 indicates interleukin 6; BMMC, bone marrow mononuclear cells; MGUS, monoclonal gammopathy of undetermined significance; and MM, multiple myeloma.
P < .01.